Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp WT
(NQ:
LEXXW
)
1.400
+0.110 (+8.53%)
Streaming Delayed Price
Updated: 3:13 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp WT
< Previous
1
2
3
4
5
6
Next >
Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
June 16, 2023
Via
ACCESSWIRE
Lexaria Appoints New Chief Financial Officer
June 12, 2023
Via
ACCESSWIRE
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
May 23, 2023
Via
ACCESSWIRE
Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
May 18, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $2M in Public Offering
May 12, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of cGMP Manufacturing for Upcoming Clinical Trial
May 11, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria Announces 2023 Annual Meeting Results
May 10, 2023
Via
ACCESSWIRE
Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
May 11, 2023
Via
ACCESSWIRE
cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
May 11, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual Meeting
May 10, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
May 08, 2023
Via
ACCESSWIRE
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
April 24, 2023
Via
ACCESSWIRE
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
May 08, 2023
Via
ACCESSWIRE
Lexaria is Receiving Four New Patents
April 20, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Encouraging Results from DehydraTECH-CBD Diabetes Study
March 02, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels
March 02, 2023
Via
ACCESSWIRE
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
February 21, 2023
Via
ACCESSWIRE
Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor
January 23, 2023
Via
ACCESSWIRE
Lexaria Releases Annual Letter from the CEO
January 13, 2023
Via
ACCESSWIRE
Lexaria Receives First Granted Patent in Canada
December 29, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD (TM) Achieves Superior CBD Blood Absorption Levels in Hypertension Study
December 21, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
December 21, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing in Its Human Oral Nicotine Study
December 20, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria’s Human Oral Nicotine Study Begins Dosing
December 20, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD(TM) Demonstrates Enhanced Performance Compared to Leading Anti-Seizure Medication
November 29, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program
November 29, 2022
Via
ACCESSWIRE
Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia
November 10, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences 1st-Ever Study Evaluating DehydraTECH-CBD’s Effect on Diabetes
November 08, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes
November 08, 2022
Via
ACCESSWIRE
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
November 01, 2022
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.